I. Ferreira-gonzalez and J. W. Busse, Heels-Ansdell D.Problems with use of composite end points in cardiovascular trials:systematic review of randomised controlled trials, Bmj, vol.334, issue.7597, p.786, 2007.

S. J. Pocock, C. A. Ariti, T. J. Collier, and D. Wang, The win ratio:a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities, Eur Heart J, vol.33, issue.2, pp.176-182, 2012.

D. M. Finkelstein and D. A. Schoenfeld, Combining mortality and longitudinal measures in clinical trials, Stat Med, vol.18, issue.11, pp.1341-1354, 1999.

P. C. Austin, D. S. Lee, and J. P. Fine, Introduction to the Analysis of Survival Data in the Presence of Competing Risks, Circulation, vol.133, issue.6, pp.601-609, 2016.

M. S. Maurer, J. H. Schwartz, and B. Gundapaneni, Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy, N Engl J Med, vol.379, issue.11, pp.1007-1016, 2018.